• Company extends expiration of special dividend for one year
• If declared, special dividend will consist of number, designation determined by company management
• BIGtoken is first consumer-managed data marketplace where people can own, earn from their data

SRAX (NASDAQ: SRAX) will extend the expiration for its previously announced BIGtoken special dividend right for one year. The dividend right was set to expire on or before 5 p.m. on Dec. 31, 2020, and that deadline has been extended to on or before 5 p.m. ET on Dec. 31, 2021 (https://ibn.fm/sCKWJ). The original dividend right was issued on Sept. 17, 2018, when SRAX, then called Social Reality Inc., announced a nontransferable right to receive at no charge a special dividend to holders of the company’s Class A common stock; the right was also extended to certain holders of the company’s common stock equivalents. The extension announcement notes that “if and when declared, the Special Dividend will consist of such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by the company’s management at their sole discretion. . . . The Special Dividend will be an analog security, i.e., not digital, and not a cryptocurrency, and the Special Dividend is expected to be a fractional non-voting security that, if and when issued, is expected to only participate in a portion of the financial performance of the BIGtoken platform.” Initially launched by SRAX and then spun off as a separate company, BIGtoken, or BIG, is a secure consumer data-management and distribution system —the first consumer-managed data marketplace where people can own and earn from their data (https://ibn.fm/nr4Sm). Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participants earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform (https://ibn.fm/gXpcG). At last count, BIGtoken has compensated more than 16 million users for access to their data while creating data sets across 25,000 unique market segments. Brands are offered access to this verified, opted-in data for a fee. “BIGtoken is a secure platform that empowers you to realize and claim the value of your digital self,” the website observes (https://ibn.fm/B0Cj3). “You have a right to privacy, awareness, and choice when it comes to the data you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 1 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
• Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
• The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
• CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.

Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.

CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.

“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).

The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.

According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.

The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).

Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Surgical imaging company Imagin Medical Inc. has developed a proprietary technology that enhances surgeons’ efforts to identify the full extent of bladder cancers and remove them
• Imagin’s i/Blue Imaging (TM) System uses blue light in combination with a fluorescent contrasting agent that highlights the tumor on an endoscope’s camera display to help surgeons remove the cancerous cells more completely than the white light standard
• Bladder cancer is the fourth most common cancer in men and the second most common genitourinary cancer
• The American Cancer Society forecasts that, during this year, about 81,400 new cases of bladder cancer would be reported and that about 17,980 people would die from the disease
• While Imagin’s initial focus is on making its technology effective and available for fighting bladder cancer, the company intends to expand its platform to work with other minimally invasive surgical procedures such as thoracic and laparoscopic

The rich blue of a daytime sky and the darker hues of a deep pool of water can evoke images of serenity for the troubled mind, while high-energy blue light at the darker end of the visible light spectrum serves health-enhancing functions such as boosting individuals’ alertness, helping memory and cognitive function, and elevating mood. It also helps to regulate the body’s natural wakefulness and sleep cycle known as the circadian rhythm (https://ibn.fm/kvAYr).

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is harnessing the virtues of blue light in an additional, health-enhancing way. By utilizing the company’s proprietary i/Blue Imaging (TM) System with a contrast agent, surgeons will be able to better visualize the parameters of cancers and then develop the appropriate response strategy.

Imagin’s platform is being developed for use in bladder cancer surgery. It relies on the drug, Cysview, which rapidly infiltrates the cancer cells and causes them to glow bright pink under blue light. The drug is administered just before surgery and the blue light is used endoscopically to locate and examine the tumor.

Endoscopic and laparoscopic imaging technology have revolutionized surgical medicine with their minimally invasive advanced optics and light sensors. Cameras and recording devices attached to long, thin tubes inserted into the body through the digestive tract or a small incision elsewhere have eliminated the need for many open surgical procedures — reducing patient anxieties and improving recovery times in the process (https://ibn.fm/VGZDU).

However, the utilization of blue light enhancement of endoscopic procedures is a relatively new development, and most surgical centers have yet to adopt it as part of their protocols. Imagin reports in a recent company webinar that the blue light procedure helps identify 25 percent more tumors but that it is used in less than 10 percent of urological procedures, despite its recommendation by the American Urological Association.

“Clearly one of the big things with patients of bladder cancer is getting it right and getting it right the first time. And we’ve been relying on white light cystoscopy for way too long,” Dr. Ashish M. Kamat, the director of the urologic oncology fellowship at the University of Texas M.D. Anderson Cancer Center in Houston, says during an interview for the webinar (https://ibn.fm/IGuqQ).

“This year itself, in 2020, we’ve had multiple efforts, editorials and workshops, to try and improve the quality of TRBT (transurethral resection of bladder tumor), and one of the ways to do that is enhanced optical cystoscopy,” Kamat adds. “Blue light really allows us to see these tumors that the naked eye, with white light, just cannot see. It allows us to do a better diagnosis, a better resection, but unfortunately a large percentage of the market today still does not have access to blue light and hence a large percentage of patients just don’t have access to the best technology that there is to offer for resection. It’s a shame!”

One benefit of Imagin’s technology is that it “addresses the limiting factors of” current systems by making its surgical light source, video camera and data recording technology adaptable to almost any scope already on the market. The light source then displays white and blue light images side-by-side on the surgeon’s monitor without a need to toggle back and forth between one image and the other.

At the beginning of 2020, the American Cancer Society estimated about 81,400 new cases of bladder cancer would be reported during the year — the vast majority of them in men (https://ibn.fm/KpvOR). The organization anticipates that, of the more than 600,000 living patients already diagnosed and treated for bladder cancer at least once, about 17,980 of them will die  . Bladder cancer is thus the second most common malignancy of the genitourinary system after prostate adenocarcinoma (https://ibn.fm/MFVl1). It is the fourth most common cancer overall in men, according to the ACS. Bladder cancer has the highest recurrence rate of all cancers at more than 50 percent, meaning patients have significant reason to worry that their cancer will return after surgery.

While Imagin’s initial focus is on improving bladder cancer surgeries, the company intends to expand its technology for other minimally invasive surgical procedures in the future, including laparoscopic, colorectal, and thoracic that use a variety of contrast dye agents, illumination sources and physical entry points.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• The Social Media Strategies Summit First Responders is a virtual conference that will take place February 2-3, 2021, and offers a unique selection of social media expert and first responders from across the country
• Attendees of the virtual conference will receive unique opportunities for one-on-on and live Q&A sessions with presenters and others in attendance
• For over a decade, the Social Media Strategies Summit has been bringing together professionals around the same common goal of upgrading online marketing, branding, and customer relations, while providing them with the platform and expertise to move forward

Since 2009, the Social Media Strategies Summit has been producing conferences for thousands of attendees interested in upgrading their online marketing, branding, and customer relations. The upcoming 2021 virtual conference is geared toward a new set of professionals: first responders and public safety professionals.

The Social Media Strategies Summit First Responders conference is scheduled to take place online February 2-3, 2021, with a vast network of agency peers in attendance from across the country. The platform will allow attending industry experts to share experiences, learn new social media strategies, and collaborate with one another virtually.

The Social Media Strategies Summit’s virtual platform offers attendees a unique participation experience, optimizing education, learning, and networking during the First Responders’ event of 2021. The conference will have three major components:

• Exhibit Hall – The virtual exhibit hall will be much like an in-person event (only online), creating an area where attendees can interact with and learn more from the vendor sponsors of the exhibit. Attendees have the opportunity to download marketing materials, learn about new services and solutions that align with their organizational needs, and chat with sales representatives one-on-one.
• Session Rooms – The virtual session rooms allow attendees to participate in activities such as live chats with other attendees, receive answers to questions through a live Q&A after each scheduled presentation, and rewatch any portion they have missed after the conference is over.
• Networking Room – Summit opportunities include a virtual networking room where attendees get the chance to further engage with others in attendance and the featured speakers. Networking rooms have topic tables to engage further based on a set area, allow for participation in a real-time event feed, and the opportunity to chat or set up one-on-one meetings through the event’s portal.

During the two-day conference, attendees who have purchased tickets will have the opportunity to attend virtual presentations from social media giants and gain first-hand advice from other first responders. A total of 15 public sessions will be organized over the two days of the event, promising fresh perspectives and valuable insights into social media for first responders, provided by industry experts from different companies and institutions, including Facebook, UC Davis Fire Department, Fort Worth Police Department, Las Vegas Fire & Rescue, ArchiveSocial, and many more.

In addition to the main event, the conference will also feature on-demand virtual sessions:

• The One-Person Social Team: Scrappy Social Media Strategies with Big Impact – Katelyn Brower, Social Media Manager, Sterling
• Attention is Everything: Using Video to Build Brand Love and Drive Attention – Charlene Tassinari & Carli Potock, Founders, Canvas+Co
• How to Choose & Optimize the Right Social Platform for your Brand – Vanessa Williams, Director of Integrated Strategy & Promotions, and Joanie Leider, Community Manager, both from Ignite Social Media
• Copy and Creative Tips on Twitter for Higher Engagement – Sara Zaccaro, Global Paid Social Strategy Lead, Accenture

Discounted early-bird tickets for those who wish to attend the Social Media Strategies Summit First Responders virtual conference are available until January 14. After that, the general admission price will go into effect, requiring attendees to “pay at the door.”

For more information or to register, visit the event’s website at www.SocialMediaStrategiesSummit.com.

• Health Canada recently granted psilocybin testing access to selected physicians
• Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues
• Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021

In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government has recently granted access to psilocybin or “psychedelic” mushrooms to several physicians for use in patients with addiction and/or mental health issues (https://ibn.fm/j9ZAO). In line with anticipated legislation expected to loosen restrictions on psilocybin mushrooms, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company with a new vertical in functional mushrooms, is currently positioning itself to be the dominant extraction company and leader in the rapid development and commercialization of functional and medicinal products. Hajdu’s comments were part of a discussion on several health-related topics at a recent Vancouver B.C. virtual townhall with the Honourable Hedy Fry, a Canadian parliament representative. In response to Fry’s questions concerning the use of psilocybin mushrooms, Hajdu disclosed that the government was taking the discussion into the mainstream by granting some physicians access to the mushrooms for testing purposes. “Health Canada approved some physicians access to psilocybin mushrooms to test,” said Hajdu. “We are still testing these mushrooms and their effects, and we are taking these discussions out of the shadows and into more of a mainstream conversation.” In anticipation of relaxed laws around the use of psilocybin mushrooms, Pure Extracts is building-out its existing cannabis-processing infrastructure to accommodate mushroom extraction processes as part of its overall market penetration strategy. The Company operates out of its state-of-the-art facility in British Columbia, Canada that is built to European Union GMP standards for the purpose of obtaining EU-GMP certification in order to export to European countries, where both cannabis and functional mushroom products are legal for sale and consumption. Rather than operate in the saturated cultivation market, Pure Extracts instead purchases in bulk from Licensed Producers for further extraction processing via a Health Canada Standard Processing License granted to Pure Extracts Manufacturing Corp., its wholly-owned subsidiary. Along with both cannabis and hemp biomass processing and white labeling for Licensed Producers, the Company has also developed private label products that include the mushroom-based ‘Pure Mushrooms’ line and the ‘Pure Pulls’ line of cannabis products. “We intend to launch these products in Q1 from an online portal that we are developing,” said Pure Extracts’ CEO, Ben Nikolaevsky (https://ibn.fm/BplTK). “Functional mushrooms have been identified as the new ‘wonder’ product in the wellness space and have been rapidly growing in popularity, so this is a very exciting move for us.” Pure Extracts was incorporated under the British Columbia Business Corporations Act and is headquartered just north of Whistler, British Columbia. Along with being granted its Standard Processing License by Health Canada on September 25, 2020, the Company also started trading on the Canadian Securities Exchange on November 5, 2020 under the symbol “PULL”. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Timing of expansion into CBD market correlated with passing of 2018 Farm Bill
• MORE Act decriminalizes marijuana, has passed the House
• Reclassification of cannabis by the UN may increase medical research, impact legalization efforts globally

Founded in 2012, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) quickly earned a reputation as one of the fastest-growing and most innovative lifestyle brands. Now a leading producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, WTER’s flagship product was a premium 8.8 pH balanced alkaline drinking water produced through an innovative, state-of-the-art proprietary electrolysis process. In 2018, WTER became publicly traded thanks to a disciplined growth strategy that soon expanded into the CBD space. The timing was perfect for this new endeavor. The 2018 Farm Bill passed, and CBD had become a buzz word in the health and wellness industry. WTER partnered with Centuria Foods and launched A88CBD(TM) in 2020, a product line (https://ibn.fm/UH2fn) that only uses CBD sourced from hemp lawfully grown and processed within the United States. But the United States hasn’t always been supportive of CBD. In 1937 under the Marihuana Tax Act, all parts of the marijuana plant were made illegal. In 1970 under the Controlled Substances Act, cannabis of any kind was prohibited. That changed in 2018 with the Farm Bill’s passing. The 2018 Farm Bill played a large part in WTER’s story and expansion by allowing for hemp cultivation and the selling of hemp products under 0.3 percent THC (https://ibn.fm/zTkyS). As new bills make their way across the House and Senate floors, WTER is looking forward to what it means for the company and the industry at large. New bills could lead to the long-awaited FDA guidance on CBD-infused consumer products. An example of this type of legislations is the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act) of 2019, which passed the House and is now awaiting approval in the Senate and then the White House. This marks the first time that a federal legislative body has ever voted to decriminalize marijuana. If the MORE Act passes both House and Senate and the President’s desk, marijuana will be removed from the list of scheduled substances. Criminal penalties will also be removed  (https://ibn.fm/SJVCe). This is a strong step forward in removing stigmas and creating therapeutic options for consumers. In addition to decriminalizing marijuana, the bill will put into motion several other changes, including:

• The ability for cannabis-related businesses to acquire loans and services not previously available
• Cannabis will no longer be used as a reason to allow for deportation or the rejection of asylum claims
• Those in prison for marijuana charges will receive a sentencing review for potentially reduced sentencing
• Federal cannabis sales tax of 5% of the sale price to pay for opportunity grants for communities most impacted by the war on drugs

The MORE Act is a step toward legal cannabis diversity and inclusion. While the future of the bill remains in question, the fact that it has progressed as far as it has indicates significant progress for cannabis in both government and popular support. And the growing acceptance and changes aren’t only being seen in the United States. The United Nations recently voted to reclassify cannabis as a less dangerous drug (https://ibn.fm/hohwB). This change holds the potential to increase medical research into the therapeutic benefits and impact legalization efforts globally. “With the apparent change in administration in the U.S., we believe that the FDA guidance on CBD will be forthcoming soon,” said WTER CEO Richard Wright (https://ibn.fm/B4qgc). “Being the National Consumer Products goods company, we feel we are positioned very well to take advantage of any changes that would allow us to sell in all the states.” For more information, visit the company’s website at www.TheAlkalineWaterCo.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• What: Clinical Document World summit, organized by Lincoln Health Network
• Where: Taking place online, with registration at https://ibn.fm/x3biD
• When: Feb. 24-26, 2021
• The summit will help professionals in the fields of pharmaceuticals, biotech, and medical device manufacture or utilization to improve their documentation experiences
• Interactive platform allows attendees to seek new information and answers to old questions from speakers and other attendees using one-on-one as well as group features

The demands of clinical documentation, particularly in light of the increased requirements resulting from the Affordable Care Act, have a tendency to produce clinician burnout, “increased cognitive load,” distractions and still result in the loss of some information (https://ibn.fm/qxjC6).

In the modern era, professionals expect to avail themselves of technological advancements to improve their performance and eliminate obstacles to productivity, and certainly automated features such as artificial intelligence-enhanced digital scribes can help capture conversations and convert them to documentation but specialized forms and other individualized elements of the clinical setting may prevent a once-size-fits-all approach.

Lincoln Health Network’s (“LHN”) Clinical Document World summit aims to deliver a one-stop learning experience for life science professionals battling to improve their documentation resources and procedures, as well as through complementary partnerships with other professionals in the fields of pharmaceuticals, biotech, and medical device manufacture or utilization (https://ibn.fm/HZmTS).

The three-day Clinical Document World event will take place Feb. 24-26 in a virtual setting given the continuing dangers posed by the COVID-19 pandemic to large public gatherings. Utilizing LHN’s virtual platform, the summit will facilitate networking, Q&A needs and interactive introductions to new things in as seamless a transition as possible from in-person gatherings. Attendees can instant message seminar presenters and other attendees at any time during the event or schedule a more personal video chat with someone.

Virtual session rooms, an exhibit hall, a networking lounge, a resource page and a real-time feed all help make the experience educational and able to generate new usefulness even after the summit has ended. The networking lounge provides great opportunities for productivity in a group, and the interactive exhibit hall allows attendees to browse some of the latest technology and services with the potential to schedule a live demo to determine if something may help the attendees’ organizations.

The 20-plus faculty roster members come from a variety of companies where they have amassed experience in trial master files (“TMF”) operations, inspection readiness, risk management and other clinical development avenues.

Following the opening day’s keynote speech on the “Impact of a Strategic Document Strategy for CRO, Sites, and Sponsors,” sessions and panels will focus on strategies for global clinical operations, metrics-friendly governance structures to accumulate useful data for inspection readiness, leveraging emerging technologies, ensuring clinical quality standards in documentation, and other related subjects.

Early bird price rates end Jan. 21, although standard and last chance ticketing will continue to be available until the event.

For further information on registration and tickets, as well as how to participate as a speaker, visit the event’s website at https://ibn.fm/6Y31C.

• Average income of a pro-esports player is $400,000
• Audience for esports is expected to reach 495 million by the end of 2020
• eSports betting market forecasted at $17.2 billion globally by the end of 2020

Mobius Interactive, an online gaming operator, is capitalizing on the quickly growing eSports segment. Through its brand, MobiusBet, the company attracts a network of high-net-worth gamers worldwide with loyalty programs, targeted gamification and product merchandising. The world of gaming has changed significantly in the last four decades, and so have the rewards. The earliest known video game competition took place at Stanford University on Oct. 19, 1972. During that competition, players competed on Spacewar for the grand prize of a one-year subscription to “Rolling Stone” (https://ibn.fm/Vfo6c). Today pro players compete online for large sums of money, and fans place bets on their favorites. In 2019, 44 million people attended the final of the League of Legends World Championship. The pandemic of 2020 only accelerated the industry’s growth. There are currently 12 professional esports leagues across the globe, 120 franchised teams and an estimated 1,000 professional players whose average salary is close to $400,000 (https://ibn.fm/3iJM4). eSsports is expected to reach a value of $1.1 billion by the end of 2020, a 15.7% increase from the previous year. The audience for esports is also growing, at 495 million this year, up 11.7% from 2019 (https://ibn.fm/RseWi). And by 2023, viewership is expected to reach 646 million (https://ibn.fm/Yj0oC). With this anticipated audience growth comes a heightened eSports betting market forecasted at $17.2 billion globally by the end of 2020 (https://ibn.fm/pFPBf). Mobius provides players with access to more than 34 eSports games and mega tournaments. Available around the clock, the platform has a wide range of functionalities, mystery jackpots, cutting-edge technology, and live and pre-match odds. The company has partnered with UltraPlay, a globally recognized, award-winning, unrivaled eSports odds and platform supplier. The esSports industry is booming, and Mobius is ideally positioned to see the greatest benefit from the boom. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• The new year, with a pro-EV president and recent inclusion into a regional municipal group purchasing program, creates exciting potential for evTS
• evTS’s vehicles and fleet-management solutions designed to provide environmentally friendly platform
• New 2021 FireFly ESV model offers attractive updated features, upgrade options

The election of a new pro-EV president, and an agreement to sell its all-electric utility vehicles through a group purchasing program, represents significant potential for ev Transportation Services. Founded in 2015, the company’s focus on its electric vehicle (“EV”) manufacturing mission could be seeing an impressive payoff in the coming months.

President-elect Joe Biden, who will be sworn into office Jan. 20, 2021, is known as a car guy who sees EVs as the future of transportation. He has announced a Cash for Clunkers–type plan that offers incentives to trade in less-efficient vehicles for America-made EVs. He has also stated that he wants to replace the government’s fleet of vehicles with EVs (https://ibn.fm/uXtpB).

In tandem with the nation’s political transition, evTS has reached an agreement with the metropolitan Boston-area Metropolitan Area Planning Council (“MAPC”) and the Greater Boston Police Council (“GBPC”) to offer its EVs for sale (https://ibn.fm/AhXRx). The agreement authorizes the company’s FireFly ESV all-electric commercial utility vehicles to be sold under the agencies’ Group Purchasing Program contract for 2021 within the 101 cities and towns of the metropolitan area.

“We are excited to include an electric vehicle manufacturer (‘evTS’) from Massachusetts in an MAPC Public Works and Public Safety Cooperative Purchasing Program for the first time,” said MAPC Director of Municipal Collaboration Mark Fine.

The company’s all-electric, light-duty commercial vehicles and fleet-management solutions provide an environmentally friendly platform using the safest lithium-ion battery technology available. They have a robust suspension design and are capable of quickly reaching speeds up to 50 mph, while still remaining highly maneuverable in tight urban situations.

In September evTS also announced its new 2021 FireFly ESV model as an upgrade to previous vehicles. The updated version will feature additional leg room and a larger door for easier access. The added features are part of an improved in-cabin experience with a modernized feel (https://ibn.fm/4TrRz).

evTS utility vehicles are fully street legal and designed to serve a wide range of functions. The company notes that its Firefly vehicles are ideal for parking management, security and perimeter patrol, parks and sidewalk maintenance, utility meter reading, property and building management, and use at airports, seaports, and university and corporate campuses. In addition, the vehicles are perfect for last mile on-demand urban delivery for shipped packages hot or cold foods and other retail products.

The 2021 model also offers upgrade features such as in-vehicle Wi-Fi and an internet-accessible vehicle-management system to allow remote diagnostics. This is on top of the FireFly ESV’s automated performance monitoring that includes low-battery warnings and other alerts. The ESV’s customizable modular design allows it to be adapted to varying service industry needs, and the 2021 model adds new rear-bed accessory options for further possibilities. Those may include an electronic lift dump, a refuse hauler, a van box, a utility bed with locking compartments and ladder racks, and other cleaning, sweeping or watering accessories that give it an advantage over the competition.

evTS is strengthening its position at an ideal time. The essential services transportation and urban mobility markets represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually, according to the company.

For more information, visit the company’s website at www.evTS.com.

NOTE TO INVESTORS: The latest news and updates relating to ev Transportation Services are available in the company’s newsroom at https://ibn.fm/EVTS

• Imperial College of London review suggests that cannabis-based medicinal products offer significant relief from intractable epilepsy
• CNSC produces proprietary CBD products under the Xceptol brand that are created with branded Technology CiBiDinol that increases absorbability, bioavailability, shelf life
• Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products

Researchers from the Imperial College of London recently conducted a review that examined the impact of cannabis-based medicinal products containing cannabidiol (“CBD”) on the frequency of epileptic seizures and determined that they offer patients significant relief from intractable epilepsy (https://ibn.fm/TDwpd). As scientific evidence supporting the use of CBD becomes mainstream, concerns about absorbability, shelf life and bioavailability continue to mount. CannAssist International (OTCQB: CNSC) is dedicated to addressing these problems through the creation of CBD products using their branded technology CiBiDinol specifically created to overcome these critical issues.  Marketed under the Xceptol consumer brand, CNSC’s line of products promise increased efficacy, absorption and bioavailability for superior results and efficiency per dose. Treating epilepsy using CBD is not a new phenomenon. One of the best-known cases dates back to 2012 and concerns Charlotte Figi, a little girl who suffered up to 300 grand mal seizures per week that kept her confined to a wheelchair. The use of CBD oil to treat her condition reduced the number of seizures to 2-3 per month and sparked the medical marijuana movement that catalyzed the lifting of prohibitions on cannabis-based products throughout the United States (https://ibn.fm/dy5YL). The Imperial College of London review mirrors those results through a study that reported a 97% reduction in the monthly frequency of seizures when patients received whole-plant extract cannabis treatment. “Patients and their families deserve better, so we implore policy makers, regulators and public health bodies to prioritize the health of these individuals and help them to access in the NHS medicines which are making a dramatic improvement to their lives,” said Rayyan Zafar, a Ph.D. candidate in the Department of Brain Sciences at the Imperial College of London (https://ibn.fm/NIb3h). Quality is a primary concern among consumers of CBD, particularly as it enters the mainstream to include new users across a wide range of demographics. CNSC uses a quality-focused proprietary process where CBD molecules are combined with penetration-enhancing cyclodextrin in order to modify the surface of the molecule and render it water dispersible. Besides enhanced potency, Xceptol products were found via third-party testing to have a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD (https://ibn.fm/PgOMt). Established in May 2017, CannAssist is headquartered in San Diego, California. The company’s Xceptol products are also sold online through the Range Me product marketplace and multiple international sales channels that include Central America, South America, South Africa, the EU, the UK and the Philippines. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC